Company Overview and News

 
Market Update: 92 stocks hit new 52-week low as midcaps remain weak; JSPL down 6%, Airtel top gainer

2018-05-10 moneycontrol
The Indian equity market was trading on flat note and shed the morning gains with the Nifty shedding 4 points and was trading at 10,737 while the Sensex was up 13 points or 0.04 percent.

 
Market Update: Nifty midcap underperforms as JP Associates, GMR Infra fall; RComm tanks 6%, ONGC top gainer

2018-05-10 moneycontrol
The Indian equity market was trading on flat note and shed the morning gains with the Nifty shedding 6 points and was trading at 10,734 while the Sensex was up 12 points or 0.04 percent.

 
Market Update: Midcap index outperforms led by TVS Motor; Adani Ports top gainer, Escorts at new 52-week high

2018-04-13 moneycontrol
The Indian equity market was trading on a positive note on Friday morning with the Nifty adding 38 points and was trading just below the 10,500 mark at 10,497 while the Sensex was up 145 points or 0.43 percent.

 
Jindal Saw Limited - Acquisition

2018-03-27 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
US duty hike: Larger repercussions for Indian steel industry

2018-03-06 moneycontrol
Though US President Donald Trump’s proposal to hike duties on steel imports may have little impact on the Indian steel industry immediately, there could be larger repercussions later on.

 
Midcap smallcap indices crack up to 3.5% as bloodbath continues on Dalal Street, PC Jeweller tanks 18%

2018-02-02 moneycontrol
It was a blood bath on Dalal Street as the the Indian markets did not take Budget 2018 in the right stride with the introduction of long-term capital gains tax on sale of listed securities on gains of over Rs 1 lakh. The Finance Minister introduced a long-term capital gains tax of 10 percent if the gains exceed Rs 100,000 without allowing the benefit of indexation.

 
Jindal Saw net profit rises 19% to Rs 96 crore

2018-01-24 moneycontrol
Pipe maker Jindal Saw today said its standalone net profit jumped 19 percent to Rs 96.23 crore during the quarter ended on December 31, 2017.

 
Jindal Saw Limited - Financial Result Updates

2018-01-24 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
Jindal Saw Limited - Updates

2018-01-24 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
Jindal Saw Limited - Registrar & Share Transfer Agent Update

2018-01-24 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
Canara Bank, Idea, Concor results on Wednesday

2018-01-23 thehindubusinessline
AB Money, Arfin India, Bharat Bijlee, Biocon, Canara Bank, Capital First, Cheviot, Concor, Dishman Carbogen, Diamines, Everest Industries, Forbes, Genus Power, Green Power, Geojit, HIL, IB Ventures, Idea, Indigo, IRB InvIT, Jindal Saw, KEI, Kirloskar Ferro, Kirloskar Bros, KRBL, Liberty Shoe, L&T Info, M&M Fin, Motilal Oswal, MphasiS, Pfizer, Pidilite, Quess, Radico, Raymond, TTK Prestige, Vijaya Bank and Wendt will announce their Q3 numbers on Wednesday.

 
Jindal Saw Limited - Results

2018-01-17 nseindia

 
Market Update: TCS, Infosys hit new 52-week high; Aban Offshore zooms 7%, Fortis Health falls 5%

2018-01-11 moneycontrol
The Indian benchmark indices on Thursday morning were trading on a negative note with the Sensex shedding 21 points and was trading at 34413 while the Nifty was down 17 points and was trading at 10614.

 
Jindal Saw Limited - Updates

2017-12-26 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

Related Articles

SGMO: Sangamo BioSciences and Research Report

2018-05-19 - Asif

OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...

HMNY: Helios and Matheson Analytics and Research Report

2018-05-19 - Asif

Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...

BSTG: Biostage Analysis and Research Report

2018-05-17 - Asif

Overview Biostage is a biotechnology company developing bioengineered organ implants based on its novel CellframeTM technology. The company's Cellframe technology is comprised of a biocompatible scaffold that is seeded with the recipient’s own stem cells. This technology is being developed to treat life-threatening conditions of the esophagus, trachea or bronchus with the objective of dramatically improving the treatment paradigm for those patients. The company believe that its Cellframe technology will provide surgeons with new ways to address damage to the esophagus, bronchus, and trachea due to congenital abnormalities, cancer, infection or trauma. Products being developed based on its Cellframe technology for those indications are called CellspanTM products. The company announced favorable preliminary pre-clinical results of large-animal studies for the esophagus, trachea and bronchus in November 2015. Since then, the Cellspan esophageal implant product candidates hav...